Atelerix: Funding, Investors & Team (Sep 2026)
Atelerix has developed a technology that allows for the storage and transportation of viable cells at room temperature, without the need for cryo-shipping. This is achieved by encapsulating the cells in a natural hydrogel, which allows for safe shipment and storage. The cells can be easily recovered when needed by adding a gentle, cell-friendly buffer. Benefits include increased predictability and reliability in drug discovery models and therapies, immediate use of cells upon arrival, elimination of the need for cryopreservation and harmful additives, and preservation of the cells' natural state without damage or alteration.
Atelerix has raised $1.6M across 3 funding rounds on record, the most recent an undisclosed round of $930k announced in Jan 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Atelerix Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Atelerix Funding Rounds
Atelerix raised $100k in an undisclosed round announced in Sep 2020.
1.4 years later, an Undisclosed of $600k was announced in Feb 2022.
2.9 years later, an undisclosed round of $930k was announced in Jan 2025.
Atelerix Founders and Leadership Team
Contact details for the Atelerix team: 1 of 1 has an email address on file.
Start 14-day free trial →Atelerix Funding Compared to Other Biotechnology Startups
Atelerix's latest round of $930k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Atelerix in Biotechnology and Newcastle
Companies Similar to Atelerix
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Atelerix Funding FAQs
What does Atelerix do?
Atelerix has developed a technology that allows for the storage and transportation of viable cells at room temperature, without the need for cryo-shipping. This is achieved by encapsulating the cells in a natural hydrogel, which allows for safe shipment and storage. The cells can be easily recovered when needed by adding a gentle, cell-friendly buffer. Benefits include increased predictability and reliability in drug discovery models and therapies, immediate use of cells upon arrival, elimination of the need for cryopreservation and harmful additives, and preservation of the cells' natural state without damage or alteration.
How much funding has Atelerix raised?
Atelerix has raised $1.6M across 3 rounds on record. The most recent is an undisclosed round of $930k announced in Jan 2025.
When did Atelerix last raise funding?
Atelerix's most recent funding round on record is an undisclosed round of $930k, announced in Jan 2025.
Who is the CEO of Atelerix?
Mick McLean is listed as CEO at Atelerix.
Where is Atelerix headquartered?
Atelerix is based in Newcastle, Newcastle Upon Tyne, United Kingdom.
How many employees does Atelerix have?
Atelerix is in the 1-10 employee band.
How does Atelerix's funding compare to other Biotechnology startups?
Atelerix's latest round of $930k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Atelerix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Atelerix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.